Literature DB >> 15190238

Phyto-oestrogens in the prophylaxis of menstrual migraine.

F Ferrante1, E Fusco, P Calabresi, L M Cupini.   

Abstract

BACKGROUND: Falling levels of estrogen is the major provocative factor in migraine associated with menstruation.
OBJECTIVE: We assessed the efficacy of the combination of two phyto-oestrogens, as perimenstrual, prophylactic treatment of menstrual migraine and tested their effect on cerebral haemodynamic. SUBJECTS AND METHODS: Women with a history of menstrual migraine (i.e., attacks occurring exclusively on day 1+/-2 days of menstruation and at no other time of the cycle) were included in the study. Eleven women fulfilling the inclusion criteria underwent to a 3-month cyclic treatment with 56 mg of genisteine and 20 mg of diadzeine per day. Transcranial doppler evaluation (TCD) was performed at baseline and after treatment.
RESULTS: Among the ten women who completed the study the average number of days with migraine during the baseline period decreased significantly after 3 months of therapy (P < 0.005). There were no major side-effects. Therapy did not affect cerebral blood flow velocities.
CONCLUSIONS: Phyto-oestrogens appear to be an effective treatment in menstrual migraine prophylaxis. This effect seems to be unrelated to cerebral hemodynamic. Placebo-controlled trials on larger number of patients are necessary to confirm our findings.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15190238     DOI: 10.1097/00002826-200405000-00010

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  11 in total

Review 1.  Menstrual migraine: what it is and does it matter?

Authors:  Letizia Maria Cupini; Ilenia Corbelli; Paola Sarchelli
Journal:  J Neurol       Date:  2020-01-28       Impact factor: 4.849

Review 2.  Prevention and treatment of menstrual migraine.

Authors:  E Anne MacGregor
Journal:  Drugs       Date:  2010-10-01       Impact factor: 9.546

Review 3.  The use of triptans in the management of menstrual migraine.

Authors:  Lisa K Mannix; Julia A Files
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 4.  Role of Estrogens in Menstrual Migraine.

Authors:  Rossella E Nappi; Lara Tiranini; Simona Sacco; Eleonora De Matteis; Roberto De Icco; Cristina Tassorelli
Journal:  Cells       Date:  2022-04-15       Impact factor: 7.666

5.  A Randomised, Double-Blind, Placebo-Controlled Crossover Trial of Resveratrol Supplementation for Prophylaxis of Hormonal Migraine.

Authors:  Jemima S A Dzator; Peter R C Howe; Kirsten G Coupland; Rachel H X Wong
Journal:  Nutrients       Date:  2022-04-22       Impact factor: 6.706

Review 6.  Hormone-related headache: pathophysiology and treatment.

Authors:  Avi Ashkenazi; Stephen D Silberstein
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

7.  Cerebral vasoconstriction reactions and plasma levels of ETBR, ET-1, and eNOS in patients with chronic high altitude disease.

Authors:  Shizheng Wu; Guisheng Hao; Shukun Zhang; Dongmei Jiang; Tana Wuren; Junming Luo
Journal:  Mol Med Rep       Date:  2016-07-27       Impact factor: 2.952

8.  Optimizing prophylactic treatment of migraine: Subtypes and patient matching.

Authors:  Michel Dib
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

Review 9.  Acute and Preventive Management of Migraine during Menstruation and Menopause.

Authors:  Raffaele Ornello; Eleonora De Matteis; Chiara Di Felice; Valeria Caponnetto; Francesca Pistoia; Simona Sacco
Journal:  J Clin Med       Date:  2021-05-24       Impact factor: 4.241

10.  Phytochemical composition of Potentilla anserina L. analyzed by an integrative GC-MS and LC-MS metabolomics platform.

Authors:  Angela Mari; David Lyon; Lena Fragner; Paola Montoro; Sonia Piacente; Stefanie Wienkoop; Volker Egelhofer; Wolfram Weckwerth
Journal:  Metabolomics       Date:  2012-11-17       Impact factor: 4.290

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.